Trial reportOphthalmology2011
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.
Trial report in Ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00105027 (The Standard Care vs. COrticosteroid for REtinal Vein Occlusion), which is not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.BMJ open · 2018Pooled it
- Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.The Cochrane database of systematic reviews · 2015Pooled it
- Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.BMJ open · 2014Pooled it
- Treatments for macular oedema following central retinal vein occlusion: systematic review.BMJ open · 2014Pooled it
- SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.American journal of ophthalmology · 2023Trial
- SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Trial
- Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.Ophthalmology. Retina · 2021Trial
- Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.BMC ophthalmology · 2019Trial
- Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.JAMA ophthalmology · 2017Trial
- Retinal microstructural disorganization in persistent macular edema secondary to branch retinal vein occlusion: an adaptive optics OCT study.Scientific reports · 2026Observational
- Influence of Social Determinants of Health on Presenting Visual Acuity in Retinal Vein Occlusions.Ophthalmology science · 2026Article
- Visual acuity and retinal thickness outcomes following anti-VEGF therapy in RVO: influence of early vs. delayed treatment.BMC ophthalmology · 2026Observational
- Hypertension, Deep Retinal Perfusion, and Concurrent Visual Acuity in Retinal Vein Occlusion: A Cross-Sectional OCTA Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Poor glycemic control impairs recovery from central retinal vein occlusion.Molecular vision · 2025Article
- Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature.Journal of clinical medicine · 2024Review
- Relationship between retinal volume changes and the prognosis of BRVO-ME treated with ranibizumab.Heliyon · 2024Article
- Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis.BMC ophthalmology · 2024Article
- Severe Macular Ischemia Is Associated with a Poor Visual Prognosis and Serious Complications in Eyes with Central Retinal Vein Occlusion.Journal of clinical medicine · 2023Article
- The Impact of Intraocular Treatment on Visual Acuity of Patients Diagnosed with Branch Retinal Vein Occlusions.Healthcare (Basel, Switzerland) · 2023Article
- Visual Prognostic Factors in Eyes with Subretinal Fluid Associated with Branch Retinal Vein Occlusion.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo investigate baseline factors associated with visual acuity and central retinal thickness outcomes in patients with macular edema secondary to retinal vein occlusion in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study.
designTwo multicenter, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and one evaluating participants with branch retinal vein occlusion (BRVO).
participantsParticipants with follow-up data of 1 year or more, including 238 with CRVO and 367 with BRVO.
methodsVisual acuity was measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) method, and central retinal thickness was measured by optical coherence tomography (OCT). Regression analysis related these outcomes to 20 baseline measures. Multiple P values were adjusted to control the false discovery rate.
main outcome measuresOutcome measures of visual acuity letter score included absolute change from baseline, a gain of ≥ 15 from baseline, and a loss of ≥ 15 from baseline. Outcome measures of center point thickness included absolute change from baseline, a measurement of ≤ 250 μm, and a measurement of ≥ 500 μm. Outcomes were assessed at 1 and 2 years.
resultsFor CRVO and BRVO, younger age was associated with improved visual acuity and central retinal thickness outcomes. For CRVO, triamcinolone treatment and less severe anatomic abnormalities of the retina (center point thickness and areas of retinal hemorrhage, thickening, and fluorescein leakage) were predictive of better visual acuity outcomes. For BRVO, no history of coronary artery disease was predictive of improved visual acuity outcomes. For center point thickness outcomes, shorter duration of macular edema was associated with improvement in both disease entities. For CRVO, higher baseline visual acuity letter score was predictive of favorable OCT outcomes. For BRVO, lower baseline visual acuity letter score, presence of dense macular hemorrhage, and no prior grid photocoagulation were predictive of favorable OCT outcomes.
conclusionsSeveral factors were predictive of better visual acuity outcomes and more favorable OCT outcomes, including younger age and shorter duration of macular edema, respectively. These factors may assist clinicians in predicting disease course for patients with CRVO and BRVO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.